BlackRock, Inc. 13D and 13G filings for CytomX Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-07-08 4:57 pm Sale |
2022-06-30 | 13G | CytomX Therapeutics, Inc. CTMX |
BlackRock Inc. BLK |
1,826,591 2.800% |
-3,135,771 (-63.19%) |
Filing |
| 2022-02-03 4:41 pm Purchase |
2021-12-31 | 13G | CytomX Therapeutics, Inc. CTMX |
BlackRock Inc. BLK |
4,962,362 7.600% |
1,157,183 (+30.41%) |
Filing |
| 2021-01-29 09:56 am Sale |
2020-12-31 | 13G | CytomX Therapeutics, Inc. CTMX |
BlackRock Inc. BLK |
3,805,179 8.200% |
-210,869 (-5.25%) |
Filing |